Comparative Pharmacology
Head-to-head clinical analysis: METANDREN versus TESTOPEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METANDREN versus TESTOPEL.
METANDREN vs TESTOPEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; binds to androgen receptors in target tissues, activating gene transcription and promoting protein synthesis, growth of male reproductive organs, and secondary sexual characteristics.
Testosterone is an androgen receptor agonist; it binds to and activates androgen receptors, leading to changes in gene expression that promote male sexual development, maintenance of secondary sexual characteristics, and anabolic effects.
Oral: 5-25 mg once daily for testosterone replacement therapy in adult males.
Subcutaneous implantation: 150-450 mg every 3-6 months. Individualize based on serum testosterone levels and clinical response.
None Documented
None Documented
The terminal elimination half-life of methyltestosterone is approximately 3-4 hours. This short half-life necessitates multiple daily dosing (e.g., 10-50 mg orally 1-3 times daily) to maintain therapeutic androgen levels. However, due to its oral administration and first-pass metabolism, the clinical effect may last longer.
Terminal half-life: 8-10 days; due to prolonged release from subcutaneous depot, effective half-life extends to 2-3 weeks.
Metandren (methyltestosterone) is primarily metabolized in the liver and excreted in the urine as glucuronide and sulfate conjugates. Approximately 90% of a dose is excreted renally, with less than 5% eliminated via feces. Biliary excretion is minimal.
Renal: ~90% as glucuronide and sulfate conjugates, ~10% unchanged; fecal: ~6% via biliary elimination.
Category C
Category C
Androgen
Androgen